Research Topics
Species | Jeffrey L CummingsSummaryAffiliation: University of California Country: USA Publications
| Collaborators
|
Detail Information
Publications
Mary S. Easton Center of Alzheimer's Disease Research at UCLA: advancing the therapeutic imperativeJeffrey L Cummings
Department of Neurology, The Mary S Easton Center for Alzheimer s Disease Research at UCLA, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
J Alzheimers Dis 19:375-88. 2010..The Center supports excellent senior 3 investigators and serves as an incubator for new scientists, agents, models, technologies and concepts that will significantly influence the future of AD treatment and AD research...
Frequency and characteristics of anxiety among patients with Alzheimer's disease and related dementiasVerna R Porter
Department of Neurology, University of California, Los Angeles, School of Medicine, USA
J Neuropsychiatry Clin Neurosci 15:180-6. 2003..These data suggest that anxiety is common among patients with diverse forms of dementia. In AD, anxiety is most common in those with more severe cognitive deterioration and an earlier age at onset...- Executive dysfunction in Alzheimer diseaseMargaret M Swanberg
Department of Neurology, David Geffen School of Medicine at UCLA, 90095-1769, USA
Arch Neurol 61:556-60. 2004..CONCLUSION: These findings support the assessment of executive function in persons with AD and the importance of frontal lobe dysfunction in AD... - Dementia with parkinsonism: what is the diagnosis?Mei S Chong
Department of Neurology, The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Rev Neurol Dis 1:41-4. 2004..The 72-year-old patient whose case is reviewed here had abnormalities in all three domains... - Mild cognitive impairment is associated with characteristic neuropsychiatric symptomsTzung J Hwang
Department of Neurology, UCLA School of Medicine, Los Angeles, CA 90095-1769, USA
Alzheimer Dis Assoc Disord 18:17-21. 2004..Psychotic symptoms are significantly more common in the early stage of AD than in MCI. These results are derived from a limited clinical sample and require confirmation in longitudinal community-based investigations... - Neuropathologic correlates of activities of daily living in Alzheimer diseaseGad A Marshall
Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095-1769, USA
Alzheimer Dis Assoc Disord 20:56-9. 2006..Deteriorating activities of daily living in Alzheimer Disease subjects correlate with greater overall pathologic burden and possibly selectively with involvement of the medial temporal, occipital, and orbital frontal regions... - Early-onset Alzheimer's disease is associated with greater pathologic burdenGad A Marshall
Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, USA
J Geriatr Psychiatry Neurol 20:29-33. 2007..This suggests that late-onset AD patients have less cognitive reserve than early-onset patients and require fewer pathologic changes to exhibit cognitive deterioration... - Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodiesJeffrey L Cummings
Department of Neurology, UCLA School of Medicine, Los Angeles, Calif, USA
Dement Geriatr Cogn Disord 13:67-73. 2002..CONCLUSIONS: This preliminary analysis suggests that olanzapine (5 or 10 mg) reduces psychosis in patients with DLB without worsening parkinsonism... - Treatment of Alzheimer's disease: current and future therapeutic approachesJeffrey L Cummings
Department of Neurology, University of California, The David Geffen School of Medicine, Los Angeles, CA, USA
Rev Neurol Dis 1:60-9. 2004..Improved methodologies for clinical trial design and analysis and the development of biological markers may hasten the identification of effective treatments for AD... - Positron emission tomography metabolic correlates of apathy in Alzheimer diseaseGad A Marshall
Department of Neurology, University of California, Los Angeles, CA, USA
Arch Neurol 64:1015-20. 2007.... - Guidelines for managing Alzheimer's disease: part I. AssessmentJeffrey L Cummings
University of California, Los Angeles, School of Medicine, USA
Am Fam Physician 65:2263-72. 2002..Suggestions for easily administered and scored assessment tools are provided, and practical tips are given for supporting primary caregivers, thereby increasing efficiency and quality of care for patients with Alzheimer's disease... - The prevalence and correlates of neuropsychiatric symptoms in a population with Parkinson's disease in MexicoJohn M Ringman
Department of Neurology, UC Irvine School of Medicine, Irvine, California, USA
Neuropsychiatry Neuropsychol Behav Neurol 15:99-105. 2002..To study the incidence of behavioral abnormalities in patients with Parkinson's disease (PD) and extend them to a Mexican population... - Association of GSK3B with Alzheimer disease and frontotemporal dementiaBarbara A J Schaffer
Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, 2506 Gonda, 695 Charles E Young Dr S, Los Angeles, CA 90095 1761, USA
Arch Neurol 65:1368-74. 2008..As a known tau kinase, GSK3B is a promising candidate gene in the remaining cases of FTD and in AD, for which tau mutations have not been found... - Treatment of Alzheimer's disease: the role of symptomatic agents in an era of disease-modifying therapiesJeffrey L Cummings
Departmentsof Neurology and Psychiatry, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Rev Neurol Dis 4:57-62. 2007..Therapeutic regimens for the treatment of AD will include both disease-modifying and symptomatic agents... - Guidelines for managing Alzheimer's disease: Part II. TreatmentJeffrey L Cummings
University of California, Los Angeles, School of Medicine, USA
Am Fam Physician 65:2525-34. 2002..Throughout the course of the disease, routine use of community resources allows care to be provided by a network of professionals, many of whom will be specialists in Alzheimer's disease... - Creativity and dementia: emerging diagnostic and treatment methods for Alzheimer's diseaseJeffrey L Cummings
UCLA Alzheimer s Disease Research Center, University of California, Los Angeles, CA, USA
CNS Spectr 13:1-20; quiz 22. 2008..Debra Cherry, PhD, discusses the advocacy needs of Alzheimer's disease patients and their caregivers. In addition, Patricia Utermohlen, MA, provides a testimonial of the impact of Alzheimer's disease on an accomplished artist... 
Biomarkers in Alzheimer's disease drug developmentJeffrey L Cummings
Cleveland Clinic Lou Ruvo Center for Brain Health, Cleveland Clinic Neurological Institute, Las Vegas, NV, USA
Alzheimers Dement 7:e13-44. 2011..Fit-for-purpose biomarkers are increasingly available to guide AD drug development decisions...- Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literatureLiana G Apostolova
Department of Neurology, David Geffen School of Medicine, UCLA, USA
Dement Geriatr Cogn Disord 25:115-26. 2008..MCI is an important risk state for dementia. Neuropsychiatric symptoms may be present in MCI... - Three-dimensional gray matter atrophy mapping in mild cognitive impairment and mild Alzheimer diseaseLiana G Apostolova
Department of Neurology, David Geffen School of Medicine, University of California at Los Angeles, 10911 Westwood Blvd, Second Floor, Los Angeles, CA 90095, USA
Arch Neurol 64:1489-95. 2007..Most patients with MCI harbor the pathologic changes of AD and demonstrate transition to dementia at a rate of 10% to 15% per year. Patients with AD and MCI experience progressive brain atrophy... - Neuropsychiatric symptoms are associated with progression from mild cognitive impairment to Alzheimer's diseaseEdmond Teng
Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 7226, USA
Dement Geriatr Cogn Disord 24:253-9. 2007..Depression and apathy may identify a subset of MCI subjects at higher risk of progression to Alzheimer's disease (AD). However, it remains uncertain whether a broader spectrum of psychopathology is associated with progression to AD... - 3D mapping of language networks in clinical and pre-clinical Alzheimer's diseaseLiana G Apostolova
Department of Neurology, David Geffen School of Medicine, UCLA, CA, USA
Brain Lang 104:33-41. 2008..Using a novel 3D mapping technique, we demonstrated that in AD language abilities are strongly influenced by the integrity of the perisylvian cortical regions... - Effective pharmacologic management of Alzheimer's diseaseMartin R Farlow
Department of Neurology, Indiana University School of Medicine, Indianapolis 46202 5111, USA
Am J Med 120:388-97. 2007.... - Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysisJeffrey L Cummings
Mary S Easton Center for Alzheimer s Disease Research at UCLA, Los Angeles, CA 90095 7226, USA
Dement Geriatr Cogn Disord 29:406-12. 2010..This was a hypothesis-forming study, designed to provide a basis for possible future research... - Increased prevalence of significant recurrent headache in preclinical familial Alzheimer's disease mutation carriersJohn M Ringman
Alzheimer s Disease Research Center, UCLA, Los Angeles, CA 90095 7226, USA
Dement Geriatr Cogn Disord 25:380-4. 2008..In our study we compared the prevalence of headaches between nondemented FAD mutation carriers (MCs) and non-mutation-carrying controls (NCs)... - Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteriaEdmond Teng
Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90073, USA
Am J Geriatr Psychiatry 16:469-77. 2008.... - Integrating ADNI results into Alzheimer's disease drug development programsJeffrey L Cummings
Mary S Easton Center for Alzheimer s Disease Research at UCLA, Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 7226, United States
Neurobiol Aging 31:1481-92. 2010.... - 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjectsLiana G Apostolova
Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States
Neurobiol Aging 31:1284-303. 2010..p-tau(181) showed stronger correlation in ApoE4 carriers, while t-tau showed stronger correlation in ApoE4 noncarriers. Of the 3 PIB measures the precuneal SUVR showed strongest associations with hippocampal atrophy... - 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCILiana G Apostolova
Department of Neurology, David Geffen School of Medicine, UCLA, CA, USA
Hum Brain Mapp 31:786-97. 2010..Greater CA1 and subicular atrophy can be demonstrated early and is predictive of future conversion to AD, whereas CA2-3 involvement becomes more evident as the disease progresses... - Subtle deficits in instrumental activities of daily living in subtypes of mild cognitive impairmentEdmond Teng
Neurobehavior Unit, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA
Dement Geriatr Cogn Disord 30:189-97. 2010..We explored the relationship between these factors by comparing instrumental activities of daily living (IADLs) among cognitive subtypes of MCI and examining associations between IADL and neuropsychological indices... - Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjectsLiana G Apostolova
Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
Neuroimage 51:488-99. 2010..After controlling for baseline hippocampal atrophy, memory performance showed regionally specific associations with hippocampal radial distance in predominantly CA1 but also in subicular distribution... - Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's diseaseJeffrey L Cummings
Mary S Easton Center for Alzheimer s Disease Research at UCLA, 10911 Weyburn Ave, Suite 200, Los Angeles, CA 90095 7226, USA
Clin Drug Investig 30:41-9. 2010..The aim of the component of the trial reported here was to evaluate the skin tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate AD... - Defining and labeling disease-modifying treatments for Alzheimer's diseaseJeffrey L Cummings
Mary S Easton Center for Alzheimer s Disease Research at UCLA, Departments of Neurology and Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Alzheimers Dement 5:406-18. 2009..Prevention claims will depend heavily on biomarker outcomes... - Current concepts of mild cognitive impairment and their applicability to persons at-risk for familial Alzheimer's diseaseJohn M Ringman
Mary S Easton Center for Alzheimer s Disease Research at UCLA, Associate Clinical Professor, UCLA Department of Neurology, 10911 Weyburn Ave, 200, Los Angeles, CA 90095 7226, USA
Curr Alzheimer Res 6:341-6. 2009..The study of FAD provides an opportunity to test various criteria for early AD and these observations should be taken into consideration in future iterations of such diagnostic criteria... - Controversies in Alzheimer's disease drug developmentJeffrey L Cummings
Departments of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Int Rev Psychiatry 20:389-95. 2008..The questions surrounding these issues must be resolved as disease-modifying therapies for AD are advanced. These controversies are framed and potential directions towards resolution described... - Behavioral effects of current Alzheimer's disease treatments: a descriptive reviewJeffrey L Cummings
UCLA Alzheimer Disease Center, UCLA, Los Angeles, CA, USA
Alzheimers Dement 4:49-60. 2008.... - Surface feature-guided mapping of cerebral metabolic changes in cognitively normal and mildly impaired elderlyLiana G Apostolova
Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, 10911 Weyburn Avenue, Los Angeles, CA 90095, USA
Mol Imaging Biol 12:218-24. 2010..The aim of this study was to investigate the longitudinal positron emission tomography (PET) metabolic changes in the elderly... - Deficits in facial emotion processing in mild cognitive impairmentEdmond Teng
Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 7226, USA
Dement Geriatr Cogn Disord 23:271-9. 2007..Patients with Alzheimer disease consistently demonstrate impaired performance on tests of facial emotion processing. However, it remains unclear how early in the neurodegenerative process these deficits emerge... - ADCS Prevention Instrument Project: behavioral measures in primary prevention trialsJeffrey L Cummings
Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1769, USA
Alzheimer Dis Assoc Disord 20:S147-51. 2006..Experimental behavioral measures were included in the protocol to examine this hypothesis... - Regression to the mean: implications for clinical trials of psychotropic agents in dementiaJeffrey L Cummings
Department of Neurology, UCLA School of Medicine, Los Angeles, CA 90095 1769, USA
Curr Alzheimer Res 1:323-8. 2004..Research design adjustments such as collection of both screening and baseline measures to determine eligibility may limit the effects of regression to the mean on trial outcomes and reduce this challenge to clinical trials... - A potential role of the curry spice curcumin in Alzheimer's diseaseJohn M Ringman
University of California, Los Angeles, Department of Neurology, Alzheimer s Disease Research Center, Los Angeles, CA 90095, USA
Curr Alzheimer Res 2:131-6. 2005..We are therefore performing a study of curcumin in patients with AD to gather this information in addition to data on the effect of curcumin on biomarkers of AD pathology... - Dementia with lewy bodies: molecular pathogenesis and implications for classificationJeffrey L Cummings
Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
J Geriatr Psychiatry Neurol 17:112-9. 2004..Classification systems based on symptom complexes related to the presence of protein misfolding will assist therapeutic decisions... - Alzheimer's diseaseJeffrey L Cummings
Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1769, USA
N Engl J Med 351:56-67. 2004 - Heterogeneous age-related breakdown of white matter structural integrity: implications for cortical "disconnection" in aging and Alzheimer's diseaseGeorge Bartzokis
Department of Neurology, Univeristy of California School of Medicine, Los Angeles, CA 90095, USA
Neurobiol Aging 25:843-51. 2004..In AD this process is globally exacerbated, consistent with an extracellular deleterious process such as amyloid beta-peptide toxicity. Non-invasive measures such as R2 may be useful in primary prevention studies of AD... - Fluctuations in cognitive function in dementia with Lewy bodiesJeffrey L Cummings
David Geffen School of Medicine, UCLA, Los Angeles, CA, USA
Lancet Neurol 3:266. 2004 - Relational integration and executive function in Alzheimer's diseaseJames A Waltz
Departjment of Psychology, University of California, Los Angeles, CA 90095-1563, USA
Neuropsychology 18:296-305. 2004.... - Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PETDaniel H S Silverman
Department of Molecular and Medical Pharmacology, University of California, Los Angeles, School of Medicine, Los Angeles, CA, USA
Mol Genet Metab 80:350-5. 2003..4). These data indicate that evaluation of brain metabolism by PET in appropriately selected patients may improve the accuracy of clinical prognostic assessment... - Speech and language in progressive nonfluent aphasia compared with early Alzheimer's diseaseMario F Mendez
Department of Neurology, David Geffen School of Medicine, University of California at Los Angeles, USA
Neurology 61:1108-13. 2003..The differentiation of PA from early Alzheimer's disease (AD) is important, given the presence of early language changes in AD... - Alzheimer's disease: from molecular biology to neuropsychiatryJeffrey L Cummings
Department of Neurology and Psychiatry, Reed Neurological Research Center, UCLA School of Medicine, Los Angeles, CA 90095 1769, USA
Semin Clin Neuropsychiatry 8:31-6. 2003..The steps of the amyloid cascade present multiple targets for drug development and identification of effective disease-modifying anti-Alzheimer's disease treatments... - Subcortical hyperintensities in Alzheimer's disease: associated clinical and metabolic findingsDavid L Sultzer
Departments of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, USA
J Neuropsychiatry Clin Neurosci 14:262-9. 2002..These preliminary findings indicate that subcortical MRI hyperintensities may play a role in the pathophysiology and clinical expression of Alzheimer's disease... - Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label studyJeffrey L Cummings
University of California, Los Angeles, Alzheimer s Disease Center, Los Angeles, California 90095 1769, USA
Am J Geriatr Pharmacother 3:137-48. 2005.... - Behavioral and neuropsychiatric outcomes in Alzheimer's diseaseJeffrey L Cummings
Alzheimer s Disease Research Center, Department of Neurology, University of California Los Angeles, 710 Westwood Plaza Rm 2 238, Los Angeles, CA 90095, USA
CNS Spectr 10:22-5. 2005.... - 3D mapping of mini-mental state examination performance in clinical and preclinical Alzheimer diseaseLiana G Apostolova
Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
Alzheimer Dis Assoc Disord 20:224-31. 2006..As a global cognitive measure, MMSE depends on the integrity of widely distributed cortical areas in both brain hemispheres with left-sided predominance... - 3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's diseaseLiana G Apostolova
Department of Neurology, David Geffen School of Medicine UCLA, CA, USA
Brain 129:2867-73. 2006..Novel hippocampal analytic techniques that can track the spread of hippocampal pathology in 3D with such precision are a promising research tool... - Neuropsychiatric and behavioral symptoms in a community sample of Hispanics with Alzheimer's diseaseFreddy Ortiz
The Neuropsychiatry Research Memory Clinic, Olive View UCLA Medical Center, Sylmar, CA 91342, USA
Am J Alzheimers Dis Other Demen 21:263-73. 2006..These findings have implications for differential sociocultural presentations of Alzheimer's disease among ethnic/racial groups... - Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatmentJeffrey L Cummings
Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1769, USA
Neurology 67:57-63. 2006..To investigate the behavioral effects of memantine in moderate to severe Alzheimer disease (AD)... - Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disordersJeffrey L Cummings
Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
Am J Geriatr Psychiatry 14:605-12. 2006..The authors report the effects of donepezil on behavioral disturbances in patients with relatively severe psychopathology at baseline... - Clinical evaluation as a biomarker for Alzheimer's diseaseJeffrey L Cummings
Department of Neurology, Alzheimer s Disease Research Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1769, USA
J Alzheimers Dis 8:327-37. 2005..Biomarkers must closely reflect clinical outcomes to be useful as evaluations of disease progression or as outcomes in clinical trials... - Treatments for behavioural disorders in neurodegenerative diseases: drug development strategiesJeffrey L Cummings
Department of Neurology, 710 Westwood Plaza, David Geffen School of Medicine, UCLA, Los Angeles, California 90095, USA
Nat Rev Drug Discov 5:64-74. 2006.... - Neuropathologic correlates of apathy in Alzheimer's diseaseGad A Marshall
Department of Neurology, University of California at Los Angeles, Reed Neurological Research Center, 2 238, 710 Westwood Plaza, CA 90095 1769, USA
Dement Geriatr Cogn Disord 21:144-7. 2006..01, and r = 0.438, p = 0.032). This analysis suggests that chronic apathy in AD correlates with a greater anterior cingulate NFT burden and that chronic behavioral changes are more reflective than acute changes of disease pathology... - Apolipoprotein E genotype and age-related myelin breakdown in healthy individuals: implications for cognitive decline and dementiaGeorge Bartzokis
Department of Neurology, The David Geffen School of Medicine at UCLA, USA
Arch Gen Psychiatry 63:63-72. 2006..This may result in a progressive "disconnection" of widely distributed neural networks that may underlie the age risk factor for AD... - Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly menPo H Lu
Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, USA
Arch Neurol 63:177-85. 2006..There is a compelling need for therapies that prevent, defer the onset, slow the progression, or improve the symptoms of Alzheimer disease (AD)... - Alzheimer diseaseJeffrey L Cummings
Department of Neurology, University of California, Los Angeles, School of Medicine, Los Angeles, CA 90095, USA
JAMA 287:2335-8. 2002 - Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutationsJohn M Ringman
UCLA Department of Neurology, Alzheimer s Disease Research Center, 10911 Weyburn Ave, Suite 200, Los Angeles, CA 90095 7226, USA
Brain 130:1767-76. 2007..Decreased FA in of the columns of the fornix is particularly robust in early FAD and may provide a biomarker for early disease in sporadic Alzheimer's disease...